Conor Medsystems (Nasdaq: CONR) is a developer of innovative controlled vascular drug delivery technologies. Conor has initially focused on the development of drug-eluting stents to treat coronary artery disease. Conor is seeking to capitalize on the full therapeutic potential of drug-eluting stents through the development of a stent specifically designed for drug delivery. Rather than retrofitting a bare metal stent with a drug coating, Conor's stent design incorporates hundreds of small holes, each acting as a reservoir into which drug-polymer compositions can be loaded. Through this proprietary design, Conor believes that it can greatly enhance control of the rate and direction of drug delivery, enable a wider range of drug therapies and potentially increase the effectiveness and range of clinical applications of drug-eluting stents.

Founders: Frank Litvack